U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C49H55N9O7
Molecular Weight 882.0171
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ELBASVIR

SMILES

COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=C(C=CC(=C6)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)OC)C(C)C)C5=C4)C9=CC=CC=C9

InChI

InChIKey=BVAZQCUMNICBAQ-PZHYSIFUSA-N
InChI=1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1

HIDE SMILES / InChI

Molecular Formula C49H55N9O7
Molecular Weight 882.0171
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Elbasvir is an inhibitor of the Hepatitis C Virus (HCV) Non-Structural protein 5A (NS5A). Elbasvir was approved by the FDA in January 2016 for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials, used in combination with the NS3/4A protease inhibitor grazoprevir under the trade name Zepatier. Zepatier is indicated for treatment of chronic HCV genotype 1 or 4 infection in adults.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
5.0 pM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZEPATIER
PubMed

PubMed

TitleDatePubMed
Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
2016
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
2016 May
Patents

Sample Use Guides

In Vivo Use Guide
ZEPATIER is a two-drug, fixed-dose combination product containing 50 mg of elbasvir and 100 mg of grazoprevir in a single tablet. The recommended dosage of ZEPATIER is one tablet taken orally once daily with or without food. ZEPATIER is used in combination with ribavirin in certain patient populations
Route of Administration: Oral
In Vitro Use Guide
Elbasvir was highly potent in GT1a wild-type replicon cells, with 90% effective concentration (EC90) value of 0.006 nM.
Substance Class Chemical
Created
by admin
on Mon Oct 21 19:49:26 UTC 2019
Edited
by admin
on Mon Oct 21 19:49:26 UTC 2019
Record UNII
632L571YDK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ELBASVIR
DASH   INN   USAN   WHO-DD  
INN   USAN  
Official Name English
ELBASVIR COMPONENT OF ZEPATIER
Common Name English
ZEPATIER COMPONENT OF ELBASVIR
Common Name English
ELBASVIR [JAN]
Common Name English
ELBASVIR [WHO-DD]
Common Name English
CARBAMIC ACID, N,N'-(((6S)-6-PHENYL-6H-INDOLO(1,2-C)(1,3)BENZOXAZINE-3,10-DIYL)BIS(1H-IMIDAZOLE-5,2-DIYL-(2S)-2,1-PYRROLIDINEDIYL((1S)-1-(1-METHYLETHYL)-2-OXO-2,1-ETHANEDIYL)))BIS-, C,C'-DIMETHYL ESTER
Common Name English
MK-8742
Code English
ELBASVIR [INN]
Common Name English
ELBASVIR [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000191256
Created by admin on Mon Oct 21 19:49:26 UTC 2019 , Edited by admin on Mon Oct 21 19:49:26 UTC 2019
WHO-ATC J05AP54
Created by admin on Mon Oct 21 19:49:26 UTC 2019 , Edited by admin on Mon Oct 21 19:49:26 UTC 2019
Code System Code Type Description
WIKIPEDIA
ELBASVIR
Created by admin on Mon Oct 21 19:49:26 UTC 2019 , Edited by admin on Mon Oct 21 19:49:26 UTC 2019
PRIMARY
RXCUI
1734628
Created by admin on Mon Oct 21 19:49:26 UTC 2019 , Edited by admin on Mon Oct 21 19:49:26 UTC 2019
PRIMARY
EPA CompTox
1370468-36-2
Created by admin on Mon Oct 21 19:49:26 UTC 2019 , Edited by admin on Mon Oct 21 19:49:26 UTC 2019
PRIMARY
CAS
1370468-36-2
Created by admin on Mon Oct 21 19:49:26 UTC 2019 , Edited by admin on Mon Oct 21 19:49:26 UTC 2019
PRIMARY
INN
9851
Created by admin on Mon Oct 21 19:49:26 UTC 2019 , Edited by admin on Mon Oct 21 19:49:26 UTC 2019
PRIMARY
EVMPD
SUB174125
Created by admin on Mon Oct 21 19:49:26 UTC 2019 , Edited by admin on Mon Oct 21 19:49:26 UTC 2019
PRIMARY
ChEMBL
CHEMBL3039514
Created by admin on Mon Oct 21 19:49:26 UTC 2019 , Edited by admin on Mon Oct 21 19:49:26 UTC 2019
PRIMARY
NDF-RT
N0000190113
Created by admin on Mon Oct 21 19:49:26 UTC 2019 , Edited by admin on Mon Oct 21 19:49:26 UTC 2019
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
LactMed
1370468-36-2
Created by admin on Mon Oct 21 19:49:26 UTC 2019 , Edited by admin on Mon Oct 21 19:49:26 UTC 2019
PRIMARY
PUBCHEM
71661251
Created by admin on Mon Oct 21 19:49:26 UTC 2019 , Edited by admin on Mon Oct 21 19:49:26 UTC 2019
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
IC50
TRANSPORTER -> SUBSTRATE
BINDER->LIGAND
BINDING
BINDER->LIGAND
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
IC50
TRANSPORTER -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC